Payment overview · 2025
General Payments
$253.24
13 reported records · 7 companies
Healthcare provider profile · identity verified
Richard B Carter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSON CITY, TN · NPI 1508065269
Verified facts
What the public records show
CMS Open Payments records show Richard B Carter, MD received $253.24 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Shingrix, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.37 | 40.4% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.68 | 15.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.49 | 11.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.14 | 9.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.96 | 8.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.00 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.60 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.24 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $82.73 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 189 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
189 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
99 | 81 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 85 |
| Lisinopril | Lisinopril | 372 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 96 |
| Alprazolam | Alprazolam | 325 | 51 |
| Gabapentin | Gabapentin | 322 | 78 |
| Omeprazole | Omeprazole | 321 | 85 |
| Simvastatin | Simvastatin | 293 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 266 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 261 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 61 |
| Losartan Potassium | Losartan Potassium | 248 | 64 |
| Tramadol Hcl | Tramadol Hcl | 247 | 49 |
| Montelukast Sodium | Montelukast Sodium | 221 | 69 |
| Glimepiride | Glimepiride | 219 | 58 |
| Meloxicam | Meloxicam | 209 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 33 |
| Furosemide | Furosemide | 201 | 59 |
| Eliquis | Apixaban | 189 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 49 |
| Metformin Hcl | Metformin Hcl | 165 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 161 | 42 |
| Metformin Hcl Er | Metformin Hcl | 150 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 53 |
| Trazodone Hcl | Trazodone Hcl | 148 | 44 |
| Famotidine | Famotidine | 130 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 25 |
| Alendronate Sodium | Alendronate Sodium | 112 | 32 |
| Estradiol | Estradiol | 112 | 30 |
| Lorazepam | Lorazepam | 111 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 33 |
| Donepezil Hcl | Donepezil Hcl | 101 | 35 |
| Prednisone | Prednisone | 99 | 53 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 99 | 81 |
| Potassium Chloride | Potassium Chloride | 98 | 28 |
| Allopurinol | Allopurinol | 97 | 30 |
| Carvedilol | Carvedilol | 96 | 24 |
| Clonazepam | Clonazepam | 96 | 16 |
| Pregabalin | Pregabalin | 96 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 27 |
| Sertraline Hcl | Sertraline Hcl | 88 | 28 |
| Atenolol | Atenolol | 86 | 24 |
| Mirtazapine | Mirtazapine | 83 | 12 |
| Fluconazole | Fluconazole | 79 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Bupropion Xl | Bupropion Hcl | 70 | 21 |
| Finasteride | Finasteride | 70 | 19 |
| Memantine Hcl | Memantine Hcl | 70 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 24 |
| Benazepril Hcl | Benazepril Hcl | 61 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 42 |
| Azithromycin | Azithromycin | 56 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Ozempic | Semaglutide | 53 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 24 |
| Ibuprofen | Ibuprofen | 51 | 12 |
| Ondansetron Odt | Ondansetron | 51 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Spironolactone | Spironolactone | 48 | 13 |
| Warfarin Sodium | Warfarin Sodium | 48 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Mupirocin | Mupirocin | 44 | 29 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 42 | 15 |
| Celecoxib | Celecoxib | 42 | 16 |
| Diazepam | Diazepam | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Naproxen | Naproxen | 35 | 11 |
| Nystatin | Nystatin | 35 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Acyclovir | Acyclovir | 32 | 11 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Temazepam | Temazepam | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Colchicine | Colchicine | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.24 · 13 records | GlaxoSmithKline, LLC. | BodyGuardian, Dexcom G6 Transmitter, ELIQUIS, ETERNA, General - Erectile Dysfunction, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error